title: Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study.
abstract: BACKGROUND
  Hodgkin's lymphoma displays distinct epidemiological attributes in Asian population thus making it relevant to study whether there are any differences in treatment outcomes too when treated with current standard of care.
  
  
  OBJECTIVE
  To evaluate the treatment outcomes of de-novo advanced stage HL in adults.
  
  
  METHODS
  This retrospective study included de-novo advanced stage HL patients (≥15 years) registered at our center from January 2004 to December 2007. Treatment outcomes were measured in terms of response rates, overall survival (OS) and progression-free survival (PFS). Overall and PFS were calculated with Kaplan-Meier methodology and Cox-proportional hazards model was used for multivariate analysis to identify prognostic factors.
  
  
  RESULTS
  There were 125 patients (males 77%) who received minimum one cycle of chemotherapy with median age of 32 years (Range 15-65 years). Stage IV disease was seen in (46 patients) 37%; 75% (94 patients) patients had B symptoms. International prognostic score (IPS) ≤4 was seen in 95/112 (85%) patients. ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy was given to 94%. Radiation to residual/bulky sites was given to 36% (45 patients). Response data was available for 112 patients; complete response in 76%; partial response in 10 % and progressive disease in 3 patients. Nineteen deaths (progressive disease-7, toxicity-8, unrelated cause-4) were observed. At median follow-up of 28 months, estimated 5-year OS and PFS were 60% and 58%, respectively. On multivariate analysis, IPS and response to treatment were significant factors for both OS and PFS.
  
  
  CONCLUSIONS
  The treatment outcomes in this study are comparable with the published literature with limited follow-up data.
authors.affiliation: Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India.
authors.forename: H
authors.initials: H
authors.lastname: Jain
authors.forename: M
authors.initials: M
authors.lastname: Sengar
authors.forename: R
authors.initials: R
authors.lastname: Nair
authors.forename: H
authors.initials: H
authors.lastname: Menon
authors.forename: S
authors.initials: S
authors.lastname: Laskar
authors.forename: T
authors.initials: T
authors.lastname: Shet
authors.forename: S
authors.initials: S
authors.lastname: Gujral
authors.forename: E
authors.initials: E
authors.lastname: Sridhar
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods*; D003606:Dacarbazine / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D007194:India; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016896:Treatment Outcome; D014747:Vinblastine / Q000627:therapeutic use
chemical_list: D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin